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Abstract 1 
 2 
Objectives: To examine the generalizability of findings from clinical trials of individuals with 3 
nicotine dependence to a large general population sample. 4 
Methods: Eligibility criteria were drawn from typical criteria of clinical trials for nicotine 5 
dependence. The National Epidemiological Survey on Alcohol and Related Conditions 6 
(NESARC), a large national sample of the United States population, was used to assess how 7 
many potentially eligible people would fulfil the eligibility criteria. NESARC interviewed 8 
more than 43,000 adults aged 18 years and older. We applied a standard set of eligibility 9 
criteria representative of smoking cessation clinical trials to all the 4,962 adults with past 12 10 
months nicotine dependence, and then to a sub-group of participants motivated to quit 11 
(n=4,121). 12 
Results: We found that approximately 6 out of ten participants (65.89%) with nicotine 13 
dependence were excluded by at least one criterion. In the sub-group of nicotine dependent 14 
participant motivated to quit, more than half (58.60%) were excluded by at least one criterion. 15 
For the overall sample, smoking 10 cigarettes per day or less and lack of motivation to quit 16 
were the two criteria leading to exclusion for the greatest percentage of individuals (32.02% 17 
and 17.60 % respectively). For the sample motivated to quit, smoking less than 10 cigarettes 18 
per day or less and current depression led most frequently to exclusion (33.79% and 15.71% 19 
respectively).  20 
Conclusions: Further studies and interventions should explore efficacy of tobacco treatment 21 
interventions in larger segment of the population, notably on the subpopulations of people 22 
with nicotine dependence who smoke less than 10 cigarettes per day or with comorbid 23 
depression. 24 
25 
3 
What this paper adds 1 
Clinical trials for treatment of nicotine dependence often exclude sizable parts of the general 2 
population with nicotine dependence. This article quantifies the lack of generalizability by 3 
using a large representative US general population survey. It was found, that the majority of 4 
nicotine dependent subjects would have been excluded from participating in clinical trials.   5 
6 
4 
Clinical guidelines are developed based on the evidence obtained using clinical trials [1-4]. In 1 
smoking cessation trials, exclusion and eligibility criteria are highly used in order to maximize 2 
treatment efficacy and safety [5]. However, they may impair the external validity of the study, 3 
since they often exclude a substantial proportion of participants, resulting in a selection bias 4 
[5], and extending the gap between research and clinical practice [6]. Common exclusion 5 
criteria include age, current or past psychiatric/drug disorder, minimal levels of tobacco use 6 
and medical conditions [7]. There is a risk that this selection of the participants involved 7 
affects the results of the treatment trial for nicotine dependence as it is the case in other 8 
domains [8, 9]. The impact of eligibility/exclusion criteria on the generalizability of clinical 9 
trials has been described for antidepressant efficacy trials [5, 10-14], antipsychotic efficacy 10 
trials [15-17] and clinical trials for alcohol dependence [18-21] and cannabis dependence [22]. 11 
The percentage of subjects excluded by these criteria ranged between 50.5% and 75.8% in 12 
these studies [10, 18]. 13 
The impact of eligibility criteria in smoking cessation trials has been discussed in the 14 
literature [7, 23-29]. As called by CONSORT guidelines, several studies reported the reasons 15 
for ineligibility [7, 28]. For example, Robinson et al. screened 1,347 adolescents for a nicotine 16 
replacement treatment trial, and found that only 24.4% were eligible for inclusion in the trial 17 
[28]. The main reason for ineligibility was a failure to meet minimum requirement regarding 18 
the number of cigarettes smoked per day and/or a low level of nicotine dependence (criterion 19 
present in 39.1% of ineligible individuals) [28]. More recently, Kamholtz et al. assessed 97 20 
non-eligible and 201 eligible participants in a laboratory research on smoking [7]. They 21 
reported that the main reasons for ineligibility were current alcohol and substance use 22 
disorders (present in 23.7% and 11.3% of ineligible individuals respectively) and failure to 23 
meet minimum requirement regarding cigarettes smoked per day (24.7%). However, when 24 
5 
comparing eligible and non-eligible participants, they found no difference in levels of nicotine 1 
dependence as assessed by the Fagerström Test for Nicotine Dependence Questionnaire [30]. 2 
 3 
A limitation of the clinical trials reported in the literature is that they rely on a sample of 4 
participants, and therefore cannot be extrapolated to individuals with nicotine dependence in 5 
the community. As suggested by Robinson et al.[28], and in order to understand the impact of 6 
eligibility criteria in the population, an analysis of the application of eligibility criteria to a 7 
representative general population sample of individuals with nicotine dependence is required. 8 
In that view, we assessed the effect of exclusion criteria commonly applied in clinical trials in 9 
a large, nationally representative sample, the National Epidemiological Survey on Alcohol 10 
and Related Conditions (NESARC). The NESARC is a survey conducted in the United States, 11 
including a broad range of psychiatric disorders as well as measures of various medical 12 
conditions. We used a method previously described by Blanco et al. in clinical trials for major 13 
depression [10] and alcohol dependence [18]. We wanted to estimate the population 14 
generalizability of clinical trials for nicotine dependent individuals. We applied common 15 
clinical trial eligibility criteria to all individuals with a current diagnosis of nicotine 16 
dependence, and then to a subsample of individuals who were motivated to quit, to examine 17 
proportion who would have been excluded in treatment trials for nicotine dependence. 18 
 19 
Methods 20 
Participants 21 
Subjects were participants in NESARC, a nationally representative face-to-face survey of 22 
43,093 respondents aged 18 years and older (response rate, 81%), conducted by the National 23 
Institute on Alcohol Abuse and Alcoholism (NIAAA) in 2001–2002 [31, 32]. The NESARC 24 
assessed the civilian non-institutionalized population residing in the United States. African-25 
6 
Americans and Hispanics were oversampled, as were young adults. The research protocol, 1 
including informed consent procedures, received full ethical review and approval from the US 2 
Census Bureau and the Office of Management and Budget. Data were adjusted for 3 
oversampling and household- and person-level nonresponse. The weighted data were then 4 
further adjusted to represent the civilian population in the United States based on the 2000 5 
Census. 6 
 7 
Measure of Nicotine Dependence 8 
The NESARC used the National Institute on Alcohol Abuse and Alcoholism's Alcohol Use 9 
Disorder and Associated Disabilities Interview Schedule DSM-IV version (AUDADIS-IV), a 10 
structured diagnostic interview made for non-clinician interviewers [33]. Algorithms were 11 
designed to produce diagnoses of nicotine dependence consistent with the final DSM-IV 12 
criteria. For example, the “using nicotine to relieve or avoid withdrawal symptoms” criterion 13 
was defined by the following 4 items: (1) the use of nicotine as soon as waking up, (2) the use 14 
of nicotine after being in a situation in which use was forbidden, (3) the use of nicotine to 15 
decrease nicotine withdrawal symptoms, and (4) waking up in the middle of the night to use 16 
tobacco [34]. Several studies have documented good to excellent retest reliability [35].  17 
 18 
Data Analysis 19 
Exclusion criteria commonly applied in clinical trials of treatments for nicotine dependence 20 
(see below in Clinical Trial Exclusion Criteria) were applied to individuals from the general 21 
population to determine the proportion of individuals from the general population with current 22 
nicotine dependence according to DSM-IV criteria that would be eligible for the clinical trials. 23 
The same criteria were applied to the subset of individuals with current nicotine dependence 24 
motivated to quit, examining potential differences in eligibility between motivated and less 25 
7 
motivated individuals, using a pattern of analysis described elsewhere [10, 18]. In these 1 
studies, Blanco et al. used attempts to quit a substance in the last 12 months as a proxy 2 
variable for motivation to quit in the future [10, 18].  3 
The appropriate statistical weight was employed when mentioned to ensure the data were 4 
representative of the population. 5 
 6 
Clinical Trial Exclusion Criteria 7 
 8 
We examined eligibility criteria from clinical trials included in a recent meta-analysis 9 
comparing the effectiveness of pharmacotherapies for smoking cessation [36]. We collected 10 
all eligibility criteria from 54 randomized clinical trials [37-92], and ranked them according to 11 
their frequency. Criteria included in more than 10% of the studies are listed in Table 1. The 12 
median of the number of eligibility criteria used in a study was 12 (considering not only 13 
criteria included in Table 1 but also criteria present in less than 10% of the studies). We thus 14 
applied the 12 most frequently used criteria to the NESARC sample.  15 
The percentages of individuals excluded by criteria 1, 3, 5, 6, 7, 8, 11 and 12 were estimated 16 
from data collected by the AUDADIS-IV. Information to approximate criterion 4 (use of 17 
psychotropic medications), criterion 9 (use of bupropion or nicotine replacement therapy) and 18 
criterion 10 (history of eating disorder) was not available in the NESARC. 19 
Criterion 1 (pregnancy status) was assessed with a single question (“Were you pregnant at any 20 
time during the past year?”). 21 
The presence of a recent cardiac event (criterion 2) was assessed by series of questions on 22 
chest pain, angina pectoris, heart attack, myocardial infarction or any other form of heart 23 
disease in the last 12 months, and whether the diagnosis was confirmed by a physician.  24 
Criterion 3 (“Smoking 10 cigarettes per day or less on average “) was applied using a 12-25 
month time frame (as it is assessed in the NESARC).  26 
8 
Criterion 5 (“Alcohol dependence “) was defined having a diagnosis of alcohol dependence 1 
within the last 12 months.  2 
Criterion 6 (“Being not motivated to quit smoking “) was assessed by 2 questions: “In you 3 
entire life, did you ever, more than once, want to stop or cut down your tobacco use?”), and 4 
“Did this happen in the last 12 months?”. Participants who respond positively to both 5 
questions were classified as being motivated to quit smoking. Other participants were 6 
classified as being not motivated to quit smoking. This assessment is therefore at variance 7 
with standard questions about motivation in research trials, who usually asked whether 8 
participants want to cut down/attempt to stop in the future rather than if they have done so in 9 
the past. 10 
Criterion 7 (“Dependence to other drugs”) was defined having a diagnosis of dependence to 11 
an illicit substance (either sedatives, tranquilizers, opiates, stimulants, hallucinogens, 12 
cannabis, cocaine (including crack cocaine), inhalants/solvents, heroin, or other drugs) within 13 
the last 12 months.  14 
Criterion 8 (“Having a current depression”) was assessed using the criteria for Major 15 
Depressive Disorder within the last 12 months. 16 
Criterion 11 (“Having a current psychosis”) was assessed by 2 questions: “Did a doctor or 17 
other health professional ever diagnose you with schizophrenia or psychotic illness or 18 
episode?”. Participants who respond positively to this were classified as having “psychosis”.  19 
Participants with a lifetime history of mania were classified as having a bipolar disorder 20 
(Criterion 12). We choose to consider only bipolar type I disorder because hypomania, the 21 
hallmark of bipolar type II disorder, is a more subtle form of the disorder and therefore not 22 
likely to be screened in routine in eligibility assessments of clinical trials for nicotine 23 
dependent individuals. For the same reason, we considered participants as having bipolar 24 
disorder if they had a history of mania even if manic episodes were induced by a substance or 25 
9 
an illness, and did not restricted our analysis to independent bipolar disorders. As a control, 1 
we did a sensitivity analysis to examine how the results would change if (i) substance and 2 
illness induced mania were ruled out, and (ii) if bipolar type II disorder was also included in 3 
the eligibility criteria (with substance and illness induced disorders being ruled out).  4 
 5 
Analysis Plan 6 
We first determined the number and percentage of nicotine dependent participants of the 7 
NESARC who would be excluded by individually applying each of the 12 most frequent 8 
eligibility criteria reported previously. . Because individuals might have been excluded by 9 
more than 1 criterion, we also calculated the overall percentage of subjects who would have 10 
been excluded by the simultaneous application of all the measurable criteria. We conducted 11 
these analyses for all individuals with a current DSM-IV diagnosis of nicotine dependence 12 
(n=4,962), and for the sub-sample of individuals who want to stop or cut down on tobacco use 13 
in the last 12 months (n=4,121). Weighted prevalence estimates and 95% confidence intervals 14 
were computed using SUDAAN, version 10.01 (Research Triangle Park, NC). This software 15 
implements a Taylor linearization to adjust for complex survey sampling design effects 16 
including clustering data. 17 
 18 
Results 19 
 20 
The percentage of subjects excluded by at least one criterion was 65.89% among respondents 21 
who met DSM-IV criteria for nicotine dependence and 58.60% of those motivated to quit 22 
smoking in the past year (Table 2) 23 
The percentage of respondents excluded due to the application of a single criterion ranged 24 
from 2.14% (lifetime diagnosis of psychosis) to 32.02% (smoking less than 10 cigarettes per 25 
10 
day) in the overall sample of respondents with nicotine dependence, and 1.95% (lifetime 1 
diagnosis of psychosis) to 33.79% (smoking less than 10 cigarettes per day) among those 2 
motivated to quit smoking.  3 
 4 
For the overall sample, smoking 10 cigarettes per day or less and lacking motivation  to quit 5 
were the two criteria including the highest percentage of individuals. For the treatment-6 
seeking sample, having a current depression and smoking 10 cigarettes per day or less were 7 
the criteria comprising the greatest percentage of individuals who would not be eligible. 8 
Current alcohol dependence and a history of bipolar disorder also excluded a notable 9 
proportion of individuals in both samples (Table 2).  10 
A history of bipolar disorder (type I) was present in 10.33 % of the participants with nicotine 11 
dependence (CI 95%: 8.16-10.50). As a control, ruling out illness- and substance-induced 12 
mania only slightly decreased to 9.26% the percentage of participants excluded because of 13 
this criteria (CI 95%:8.16-10.50). When bipolar type II disorder was also included in this 14 
eligibility criteria (substance- and illness-induced disorder still ruled out), the percentage of 15 
participants excluded because of this criteria raised to 14.70% (95%CI: 13.55-15.93). The 16 
overall exclusion rate was 65.58% when considering bipolar I disorder after ruling out illness 17 
and substance induced mania, and 66.8% when considering bipolar I and II after ruling out 18 
illness and substance induced mania, compared to an overall exclusion rate of 64.13% when 19 
considering only bipolar I disorder even if manic episodes were induced by a substance or an 20 
illness. This suggests that the criteria used to define bipolar disorder have little or no impact 21 
on the overall inclusion rate. 22 
More than 6 out of ten respondents from the full nicotine dependent sample and more than 23 
half of the subsample of individuals motivated to quit smoking would have been excluded by 24 
one or more of the study criteria. 25 
11 
 1 
Discussion 2 
 3 
This study ascertains the proportion of community-dwelling adults with nicotine dependence 4 
that would have been eligible for a typical nicotine dependence treatment study. The results of 5 
this study suggest that traditional criteria used in nicotine dependence trials tend to exclude 6 
from participation half of individuals with nicotine dependence who are likely to seek out a 7 
treatment. These results are in line with previous findings, suggesting that a majority of 8 
individuals who were screened for a nicotine cessation trail were not eligible to participate to 9 
the trial. For example, among the 54 randomized clinical trials assessed in the present paper 10 
[37-92], the ineligibility rates varied widely, ranging from 12.9% [37]to 85.31[56].. 11 
Consistent with the existing literature, we found that a lack of motivation to quit and a low 12 
level of cigarette consumption explain a large proportion of ineligibility [7, 28].  13 
 14 
Our study has several limitations. 15 
First of all, our exclusion criteria are somehow arbitrary. ,We considered eligibility criteria 16 
from 54 randomized clinical trials included in a recent meta-analysis [36],  but the use of 17 
another methodology could have led to other results. An important point is that the exclusion 18 
criterion based on alcohol consumption varies widely across studies. It has been emphasized 19 
that an alcohol-related exclusion criterion appears frequently in smoking cessation 20 
pharmacotherapy trials [29, 93]. A recent review showed that 41.6% of trials (45 of 125 21 
nicotine replacement trails, 15 of 22 bupropion trials and 3 of 3 varenicline trials) involved 22 
exclusion of participants with either current or recent alcohol problems, leading to a lack of 23 
information on the effects of alcohol use disorders on smoking cessation [29, 93]. 24 
A second restriction is that 3 of the 12 exclusion criteria initially included could not be 25 
operationalized in our study, because the relevant information was not assessed in the 26 
12 
NESARC sample, including (1) participants currently taking a psychotropic medication, (2) 1 
participants “currently taking  Bupropion or nicotine replacement therapy”, and (3) having an 2 
eating disorder,. This may theoretically lead to an underestimation of the proportion of 3 
patients excluded in clinical trials. However, these criteria are rarely met in the general 4 
population. For example, the estimated percentage of smokers in Australia who used 5 
bupropion in a year was only 3.6% in 2005 [94]. Eating disorders have a low prevalence, 6 
affecting less than 4.5% [95] of the general population. While an investigation of the impact 7 
of these exclusion criteria on the generalizability of clinical trials is required in a future study, 8 
they are not likely to exclude a significant proportion of smokers. 9 
A third limitation is that the NESARC sample included only individuals aged 18 years or 10 
older. Information was unavailable for adolescents, who may be have a lower level of 11 
comorbidities, and may therefore be more likely to be eligible for clinical trials. 12 
Some of the criteria have been implemented for safety reasons (e.g pregnancy, potential 13 
interaction with psychotropic drugs or with alcohol) while some other may contribute to 14 
stigmatize a significant proportion of the population (e.g having a history of substance abuse 15 
with no use within the last 12 months should not be considered as valid exclusion criteria in a 16 
clinical trial).  17 
The exclusion of participant with alcohol dependence is particularly damageable, since 18 
nicotine dependence is a major issue in alcohol-dependent patients. For example, smokers 19 
with a lifetime history of alcohol dependence are more likely to die of smoking-related 20 
diseases rather than from alcohol-related diseases [96].  Moreover, alcohol-dependent subjects 21 
suffering from nicotine dependence have a higher prevalence of nearly all psychiatric and 22 
addictive disorders [97], making treatment for smoking cessation in this specific population a 23 
unmet need. 24 
13 
In summary, we found that the current criteria of eligibility applied in clinical trial involving 1 
nicotine dependent individuals are highly restrictive, and exclude a majority of participants, 2 
thus limiting the generalizability of their findings. Particularly, our findings suggested that (1) 3 
individuals smoking few cigarettes in a day or (2) having a current or past history of mood 4 
disorders (major depressive disorder or bipolar disorder) are underrepresented in clinical 5 
trials. These two related groups should be the focus of further investigations. 6 
7 
14 
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Table 1. Eligibility criteria in 54 randomized clinical trials assessing pharmacotherapies 1 
for smoking cessation 2 
 3 
 4 
Eligibility criteria present in more 
than 10% of the studies (ranked by 
frequency) 
Studies using the criteria [reference number] Number of 
studies using the 
criteria 
N=54 
1. Pregnancy [37, 38, 43-48, 50-54, 56, 58-65, 67-69, 71-82, 
84, 98, 99] 
40 
2. Cardiovascular disorder [37, 38, 41-46, 48, 49, 51-53, 58-62, 64, 65, 67-
69, 71-76, 78-82, 84, 85, 92, 98, 99] 
38 
3. Smoking at least 10 cigarettes 
per day on average 
[37-49, 53-56, 58-63, 66, 67, 69-74, 76, 78, 79, 
83, 89, 92] 
37 
4. Currently/past 6 months take 
any psychotropic medication 
[38, 39, 42, 45, 47, 49, 52-54, 56, 58-60, 62-64, 
66-72, 74-76, 78, 79, 81, 82, 89] 
32 
5. Alcohol dependence [38, 40-44, 47, 48, 50, 53, 54, 58-60, 62-65, 68, 
70-72, 74-76, 78, 79, 81, 82, 86] 
30 
6. Motivated to quit [37-39, 43, 44, 46, 48-51, 54, 55, 58, 59, 61, 63, 
65, 67, 69, 71-73, 76, 78, 79, 81, 82, 87, 98] 
29 
7. Dependence to other drugs [38, 40-44, 50, 54, 58-60, 62-66, 68, 70-72, 74-
76, 78, 79, 81, 82] 
27 
8. Having a current depression [37, 38, 40-43, 45-49, 52, 54, 55, 59, 63, 66, 70, 
73, 74, 76, 77] 
22 
9. Currently/past 6 months take 
Bupropion and/or NRT 
[39-43, 46, 51-55, 58, 59, 61, 63, 64, 66, 69, 78, 
81, 87] 
21 
10. Eating disorder [37-39, 41-44, 47-49, 52, 54, 55, 59, 63, 66, 70, 
73, 74, 76] 
20 
11. Having a current psychosis [37, 38, 40-43, 47-49, 52, 59, 63, 66, 70, 73, 74, 
76, 77, 86] 
19 
12. Bipolar disorder [37, 38, 40-43, 47-49, 52, 59, 63, 66, 70, 73, 74, 
76, 77] 
18 
13. Having current Panic disorder [37, 38, 40-43, 47-49, 59, 63, 66, 70, 73, 74, 76, 
77] 
17 
14. Using any form of tobacco 
other than cigarettes 
[38, 40, 42, 46, 48, 53, 59-61, 64, 71, 74, 75, 
79, 82, 87] 
16 
15. Age less than 75 yo [38, 40-45, 60, 62, 69, 74-77, 81, 99] 16 
16. Renal disease [37-39, 41-46, 48, 49, 55, 59, 92] 14 
17. History/risk of seizure [39, 41, 43, 44, 46-49, 52, 54, 55, 59, 63] 13 
16 
18. High blood pressure [41-45, 48, 49, 51, 59, 68, 69, 72, 81] 13 
19. Liver disease [37-39, 41-46, 48, 49, 55, 92] 13 
20. Skin disorder [58, 60, 62, 67, 69, 71, 73, 74, 76, 77, 79, 80, 
82] 
13 
21. Neurological disease [37-39, 41, 44, 48, 49, 55, 59, 92] 10 
22. Peptic ulcer disease [45, 51, 59, 68, 71, 72, 80, 84, 99] 9 
23. Diabetes  [9, 13, 22-24, 35, 38, 51, 53] 9 
24. High alveolar carbon 
monoxide level 
[53, 55, 56, 70, 74, 76] 6 
25. Allergies [43, 48, 52, 65, 69, 70] 6 
   
Studies who did not reported any 
inclusion/exclusion criteria 
[55-59] 5 
 1 
 2 
 3 
4 
17 
Table 2. Estimated percentage of adults with nicotine dependence in the NESARC 1 
excluded from typical clinical trials of treatments for nicotine dependence by traditional 2 
efficacy eligibility criteria 3 
 4 
Exclusion Variable Current nicotine 
dependence 
(N=4,962) 
% (95% CI) 
Motivated to quit 
smoking sample  
(N=4,121) 
 % (95% CI) 
Traditional efficacy exclusion criteriaa   
 1. Pregnancy 3.19 (2.67-3.80) 3.46 (2.89-4.13) 
 2. Cardiovascular disorder 6.84 (5.99-7.80) 6.66 (5.77-7.68) 
 3. Smoking less than 10 cigarettes per day on 
average 
32.02 (29.98-34.14) 33.79 (31.79-35.85) 
 4. Currently/past 6 months take any 
psychotropic medication 
NA NA 
 5. High alcohol consumption/alcohol abuse 13.55 (12.27-14.82) 12.96 (11.73-14.30) 
 6. Not motivated to quit 17.60 (16.18-19.11)_ 0.00 
 7. Use/abuse of other drugs 3.40 (2.83-4.07) 3.24 (2.64-3.98) 
 8. Having a current depression 16.62 (15.41-17.92) 15.71 (14.41-17.10) 
 9. Currently/past 6 months take Bupropion 
and/or NRT 
NA NA 
 10. Eating disorder NA NA 
 11. History of psychosis 2.14 (1.72-2.67) 1.95 (1.52-2.51) 
 12. History of bipolar disorder 10.33 (9.13-11.66) 9.81 (8.59-11.18) 
    
Exclusion by any criterion 65.89 (64.13-67.60) 58.60 (56.57-60.61) 
a
 Derived from the review of 54 randomized controlled clinical trials (method described in the 5 
paper). 6 
18 
 1 
Percentages are weighted values 2 
NA: Information not available in the NESARC 3 
4 
19 
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